Competitive Landscape Of Top mRNA Synthesis Raw Material Suppliers

Report Overview

The COVID-19 pandemic brought mRNA vaccines to the forefront, highlighting their rapid development and high efficacy in addressing urgent health needs. While the focus has largely been on COVID-19 vaccines, a significant amount of research is being conducted on mRNA vaccines for cancer treatment. Numerous clinical trials, particularly for personalized cancer vaccines, are either completed or ongoing, with results expected in the next 2 to 4 years. Positive outcomes in these trials could further propel the mRNA industry forward, expanding its applications beyond infectious diseases to include cancer therapeutics.

The mRNA platforms are gaining prominence as a result of their fast development time, lower relative manufacturing costs, and proven safety profile. The competitive landscape for mRNA technology is vibrant, driven by its proven success in vaccines, broad therapeutic potential, significant funding influx, technological advancements, and a growing market. Some key players in the market are F. Hoffmann-La Roche Ltd.; Jena Bioscience GmbH; Merck KGaA; Yeasen Biotechnology (Shanghai) Co., Ltd.; BOC Sciences; Thermo Fisher Scientific, Inc.; Maravai LifeSciences; New England Biolabs; Creative Biogene; and HONGENE among several others.

Leading mRNA Synthesis Raw Material Suppliers

Maravai LifeSciences

Establishment Year – 2014

Headquarters - California, U.S

Maravai LifeSciences offers solutions for drug development, diagnostics, novel vaccine production, and research. The company drives the development of drug therapies & vaccines and supports human disease research activities through its portfolio of reagents, assays, and proprietary technologies. The company operates through two business segments, namely, Biologics Safety Testing and Nucleic Acid Production. Under the Nucleic Acid Production, the company has four business units. TriLink Discovery, TriLink GMP, Glen Research, and Alphazyme.

The first two vaccines authorized for use in response to the COVID-19 pandemic were mRNA vaccines. Among these, the vaccine developed by Pfizer and BioNTech incorporates the CleanCap product. This same CleanCap technology is also used in the booster vaccines developed by Pfizer and BioNTech.

The company generated a total revenue of USD 288.9 million for the year ended December 31, 2023. The Nucleic Acid Production revenue decreased by 72.4% from 2022 primarily due to decreased revenue from CleanCap analogs as demand declined from COVID-19 vaccine manufacturers.

List Of Notable Companies Offering mRNA Synthesis Raw Materials

Report Scope

Several companies are undertaking various organic and inorganic developments to meet the growing demand for mRNA raw materials. These strategies enable companies to adapt to the rapidly growing demand for mRNA synthesis raw materials and support the development and production of mRNA-based vaccines and therapeutics.

Key Players' Latest Strategic Initiatives to Boost Market Presence

Expanding Production Capacity: Key players like Marvai LifeSciences, and Danaher, among others are investing in expanding their manufacturing facilities to increase the supply of critical raw materials for mRNA synthesis.

• In April 2024, TriLink BioTechnologies opened a new cGMP mRNA manufacturing facility in San Diego, U.S. The 32,000 square meter facility is specifically designed for mRNA production to support drug developers from Phase 2 to commercialization through TriLink's mRNA production capabilities.

• In May 2023, Aldevron, a part of Danaher, announced a plan to expand its mRNA manufacturing units. This expansion included the incorporation of Lipid Nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities, enabling the company to provide an extended spectrum of facilities to prospective collaborators.

Developing Innovative Technologies: Companies are focusing on advancements in capping technology and other mRNA synthesis processes to improve efficiency and reduce costs.

• In July 2023, Applied DNA Sciences, Inc. announced the launch of Linea IVT platform evaluation kits to minimize impurities and lower production expenses for mRNA therapies, such as the COVID-19 vaccines.

• In August 2022, New England Biolabs introduced the Faustovirus Capping Enzyme (FCE), a capping solution for mRNA with a high degree of activity and a wide temperature range, to serve the needs of mRNA therapeutic manufacturing.

  

Collaborations & Partnerships: Pharmaceutical, and biotech companies as well as academic and research centers are collaborating with raw material suppliers to secure their supply chains and ensure continuous production. The following are a few examples in this regard.

• In May 2024, TriLink BioTechnologies (part of Maravai LifeSciences) collaborated with Johns Hopkins University to accelerate transformational research in RNA discovery. Under the terms of this collaboration, TriLink's investment includes direct funding for the center and access to TriLink's in vitro translation technology, CleanScript, which enables Hopkins researchers to advance mRNA development.

• In February 2022, Thermo Fisher Scientific entered into a 15-year strategic collaboration with Moderna for large-scale manufacturing of its COVID-19 vaccine and further investigational mRNA medicines in its pipeline.